Advancements In ADCs Using SMARTag Technology

Source: Catalent

Catalent’s SMARTag® technology platform offers ADC and biologics developers a one-step toolkit to develop optimized ADCs and bioconjugates. The SMARTag® technology enables site-specific, controlled drug-protein conjugation, and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering.

Hear Penelope Drake, Director of R&D for Catalent Biologics, present on the demonstrated success of SMARTag® across several therapeutic modalities in this on-demand webinar.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader